Flu Vax Giant Sanofi Defends Corner With $650m Protein Sciences Buy
In agreeing a $650m+ deal to acquire privately owned Protein Sciences, Sanofi is defending its market dominance in influenza vaccinations by adding an approved non-egg based product. The purchase may also help it defend its position in the section of the market targeting elderly patients, since its current trivalent offering is threatened by a rival quadrivalent product from Seqirus.
You may also be interested in...
Sanofi Starts 2018 As It Means To Go On: More Transactions Expected
This year Sanofi will "begin to make our success sustainable," said CEO Olivier Brandicourt in a 2017 financial earnings broadcast; despite a weak finish to 2017 and lower than expected guidance for this year, Sanofi's chief exec is upbeat.
Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry
Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.
Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.